ImmunoScape Partners with Singapore’s Experimental Drug Development Centre
MiNK Therapeutics combines its unique, proprietary library of T-cell antigens with ImmunoScape™s cutting-edge platform for rapid discovery of novel T-cell receptors Therapeutic development to focus on...
ImmunoScape Appoints Systems Immunology and Computational Biology Expert Dr. John Tsang to its Scientific Advisory Board
ImmunoScape Uses Machine Learning to Accurately Predict Antigen Specificity Based on T-Cell Phenotypes in New Peer-Reviewed Research
SAN DIEGO & SINGAPORE--(BUSINESS WIRE)--ImmunoScape, a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR-T-cell therapeutics today announced that it has raised $14M in new financing. Existing investor Anzu Partners led the round with participation from new investor Amgen Ventures and Singapore-based global investor EDBI.
SINGAPORE & SAN DIEGO & OKLAHOMA CITY & AUSTIN, Texas--(BUSINESS WIRE)--ImmunoScape, a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology, today announced that it has signed a licensing deal with Pure MHC, LLC, a target discovery and development company, to pursue TCR-T therapeutics against Pure MHC-identified antigens in lung cancer, colorectal cancer, and other cancer indications.